CERO Therapeutics Sells U.S. Subsidiary to SRX Global
CERO Therapeutics entered into a definitive stock purchase agreement to sell its subsidiary CERO Therapeutics, Inc. to SRX Global for shares of SRX common stock and the forgiveness of a secured promissory note.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed